Cargando…
Human iPSC-derived hepatocyte system models cholestasis with tight junction protein 2 deficiency
BACKGROUND & AIMS: The truncating mutations in tight junction protein 2 (TJP2) cause progressive cholestasis, liver failure, and hepatocyte carcinogenesis. Due to the lack of effective model systems, there are no targeted medications for the liver pathology with TJP2 deficiency. We leveraged the...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8904612/ https://www.ncbi.nlm.nih.gov/pubmed/35284810 http://dx.doi.org/10.1016/j.jhepr.2022.100446 |
_version_ | 1784664993255391232 |
---|---|
author | Li, Chao Zheng Ogawa, Hiromi Ng, Soon Seng Chen, Xindi Kishimoto, Eriko Sakabe, Kokoro Fukami, Aiko Hu, Yueh-Chiang Mayhew, Christopher N. Hellmann, Jennifer Miethke, Alexander Tasnova, Nahrin L. Blackford, Samuel J.I. Tang, Zu Ming Syanda, Adam M. Ma, Liang Xiao, Fang Sambrotta, Melissa Tavabie, Oliver Soares, Filipa Baker, Oliver Danovi, Davide Hayashi, Hisamitsu Thompson, Richard J. Rashid, S. Tamir Asai, Akihiro |
author_facet | Li, Chao Zheng Ogawa, Hiromi Ng, Soon Seng Chen, Xindi Kishimoto, Eriko Sakabe, Kokoro Fukami, Aiko Hu, Yueh-Chiang Mayhew, Christopher N. Hellmann, Jennifer Miethke, Alexander Tasnova, Nahrin L. Blackford, Samuel J.I. Tang, Zu Ming Syanda, Adam M. Ma, Liang Xiao, Fang Sambrotta, Melissa Tavabie, Oliver Soares, Filipa Baker, Oliver Danovi, Davide Hayashi, Hisamitsu Thompson, Richard J. Rashid, S. Tamir Asai, Akihiro |
author_sort | Li, Chao Zheng |
collection | PubMed |
description | BACKGROUND & AIMS: The truncating mutations in tight junction protein 2 (TJP2) cause progressive cholestasis, liver failure, and hepatocyte carcinogenesis. Due to the lack of effective model systems, there are no targeted medications for the liver pathology with TJP2 deficiency. We leveraged the technologies of patient-specific induced pluripotent stem cells (iPSC) and CRISPR genome-editing, and we aim to establish a disease model which recapitulates phenotypes of patients with TJP2 deficiency. METHODS: We differentiated iPSC to hepatocyte-like cells (iHep) on the Transwell membrane in a polarized monolayer. Immunofluorescent staining of polarity markers was detected by a confocal microscope. The epithelial barrier function and bile acid transport of bile canaliculi were quantified between the two chambers of Transwell. The morphology of bile canaliculi was measured in iHep cultured in the Matrigel sandwich system using a fluorescent probe and live-confocal imaging. RESULTS: The iHep differentiated from iPSC with TJP2 mutations exhibited intracellular inclusions of disrupted apical membrane structures, distorted canalicular networks, altered distribution of apical and basolateral markers/transporters. The directional bile acid transport of bile canaliculi was compromised in the mutant hepatocytes, resembling the disease phenotypes observed in the liver of patients. CONCLUSIONS: Our iPSC-derived in vitro hepatocyte system revealed canalicular membrane disruption in TJP2 deficient hepatocytes and demonstrated the ability to model cholestatic disease with TJP2 deficiency to serve as a platform for further pathophysiologic study and drug discovery. LAY SUMMARY: We investigated a genetic liver disease, progressive familial intrahepatic cholestasis (PFIC), which causes severe liver disease in newborns and infants due to a lack of gene called TJP2. By using cutting-edge stem cell technology and genome editing methods, we established a novel disease modeling system in cell culture experiments. Our experiments demonstrated that the lack of TJP2 induced abnormal cell polarity and disrupted bile acid transport. These findings will lead to the subsequent investigation to further understand disease mechanisms and develop an effective treatment. |
format | Online Article Text |
id | pubmed-8904612 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-89046122022-03-10 Human iPSC-derived hepatocyte system models cholestasis with tight junction protein 2 deficiency Li, Chao Zheng Ogawa, Hiromi Ng, Soon Seng Chen, Xindi Kishimoto, Eriko Sakabe, Kokoro Fukami, Aiko Hu, Yueh-Chiang Mayhew, Christopher N. Hellmann, Jennifer Miethke, Alexander Tasnova, Nahrin L. Blackford, Samuel J.I. Tang, Zu Ming Syanda, Adam M. Ma, Liang Xiao, Fang Sambrotta, Melissa Tavabie, Oliver Soares, Filipa Baker, Oliver Danovi, Davide Hayashi, Hisamitsu Thompson, Richard J. Rashid, S. Tamir Asai, Akihiro JHEP Rep Research Article BACKGROUND & AIMS: The truncating mutations in tight junction protein 2 (TJP2) cause progressive cholestasis, liver failure, and hepatocyte carcinogenesis. Due to the lack of effective model systems, there are no targeted medications for the liver pathology with TJP2 deficiency. We leveraged the technologies of patient-specific induced pluripotent stem cells (iPSC) and CRISPR genome-editing, and we aim to establish a disease model which recapitulates phenotypes of patients with TJP2 deficiency. METHODS: We differentiated iPSC to hepatocyte-like cells (iHep) on the Transwell membrane in a polarized monolayer. Immunofluorescent staining of polarity markers was detected by a confocal microscope. The epithelial barrier function and bile acid transport of bile canaliculi were quantified between the two chambers of Transwell. The morphology of bile canaliculi was measured in iHep cultured in the Matrigel sandwich system using a fluorescent probe and live-confocal imaging. RESULTS: The iHep differentiated from iPSC with TJP2 mutations exhibited intracellular inclusions of disrupted apical membrane structures, distorted canalicular networks, altered distribution of apical and basolateral markers/transporters. The directional bile acid transport of bile canaliculi was compromised in the mutant hepatocytes, resembling the disease phenotypes observed in the liver of patients. CONCLUSIONS: Our iPSC-derived in vitro hepatocyte system revealed canalicular membrane disruption in TJP2 deficient hepatocytes and demonstrated the ability to model cholestatic disease with TJP2 deficiency to serve as a platform for further pathophysiologic study and drug discovery. LAY SUMMARY: We investigated a genetic liver disease, progressive familial intrahepatic cholestasis (PFIC), which causes severe liver disease in newborns and infants due to a lack of gene called TJP2. By using cutting-edge stem cell technology and genome editing methods, we established a novel disease modeling system in cell culture experiments. Our experiments demonstrated that the lack of TJP2 induced abnormal cell polarity and disrupted bile acid transport. These findings will lead to the subsequent investigation to further understand disease mechanisms and develop an effective treatment. Elsevier 2022-02-01 /pmc/articles/PMC8904612/ /pubmed/35284810 http://dx.doi.org/10.1016/j.jhepr.2022.100446 Text en © 2022 The Author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Research Article Li, Chao Zheng Ogawa, Hiromi Ng, Soon Seng Chen, Xindi Kishimoto, Eriko Sakabe, Kokoro Fukami, Aiko Hu, Yueh-Chiang Mayhew, Christopher N. Hellmann, Jennifer Miethke, Alexander Tasnova, Nahrin L. Blackford, Samuel J.I. Tang, Zu Ming Syanda, Adam M. Ma, Liang Xiao, Fang Sambrotta, Melissa Tavabie, Oliver Soares, Filipa Baker, Oliver Danovi, Davide Hayashi, Hisamitsu Thompson, Richard J. Rashid, S. Tamir Asai, Akihiro Human iPSC-derived hepatocyte system models cholestasis with tight junction protein 2 deficiency |
title | Human iPSC-derived hepatocyte system models cholestasis with tight junction protein 2 deficiency |
title_full | Human iPSC-derived hepatocyte system models cholestasis with tight junction protein 2 deficiency |
title_fullStr | Human iPSC-derived hepatocyte system models cholestasis with tight junction protein 2 deficiency |
title_full_unstemmed | Human iPSC-derived hepatocyte system models cholestasis with tight junction protein 2 deficiency |
title_short | Human iPSC-derived hepatocyte system models cholestasis with tight junction protein 2 deficiency |
title_sort | human ipsc-derived hepatocyte system models cholestasis with tight junction protein 2 deficiency |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8904612/ https://www.ncbi.nlm.nih.gov/pubmed/35284810 http://dx.doi.org/10.1016/j.jhepr.2022.100446 |
work_keys_str_mv | AT lichaozheng humanipscderivedhepatocytesystemmodelscholestasiswithtightjunctionprotein2deficiency AT ogawahiromi humanipscderivedhepatocytesystemmodelscholestasiswithtightjunctionprotein2deficiency AT ngsoonseng humanipscderivedhepatocytesystemmodelscholestasiswithtightjunctionprotein2deficiency AT chenxindi humanipscderivedhepatocytesystemmodelscholestasiswithtightjunctionprotein2deficiency AT kishimotoeriko humanipscderivedhepatocytesystemmodelscholestasiswithtightjunctionprotein2deficiency AT sakabekokoro humanipscderivedhepatocytesystemmodelscholestasiswithtightjunctionprotein2deficiency AT fukamiaiko humanipscderivedhepatocytesystemmodelscholestasiswithtightjunctionprotein2deficiency AT huyuehchiang humanipscderivedhepatocytesystemmodelscholestasiswithtightjunctionprotein2deficiency AT mayhewchristophern humanipscderivedhepatocytesystemmodelscholestasiswithtightjunctionprotein2deficiency AT hellmannjennifer humanipscderivedhepatocytesystemmodelscholestasiswithtightjunctionprotein2deficiency AT miethkealexander humanipscderivedhepatocytesystemmodelscholestasiswithtightjunctionprotein2deficiency AT tasnovanahrinl humanipscderivedhepatocytesystemmodelscholestasiswithtightjunctionprotein2deficiency AT blackfordsamuelji humanipscderivedhepatocytesystemmodelscholestasiswithtightjunctionprotein2deficiency AT tangzuming humanipscderivedhepatocytesystemmodelscholestasiswithtightjunctionprotein2deficiency AT syandaadamm humanipscderivedhepatocytesystemmodelscholestasiswithtightjunctionprotein2deficiency AT maliang humanipscderivedhepatocytesystemmodelscholestasiswithtightjunctionprotein2deficiency AT xiaofang humanipscderivedhepatocytesystemmodelscholestasiswithtightjunctionprotein2deficiency AT sambrottamelissa humanipscderivedhepatocytesystemmodelscholestasiswithtightjunctionprotein2deficiency AT tavabieoliver humanipscderivedhepatocytesystemmodelscholestasiswithtightjunctionprotein2deficiency AT soaresfilipa humanipscderivedhepatocytesystemmodelscholestasiswithtightjunctionprotein2deficiency AT bakeroliver humanipscderivedhepatocytesystemmodelscholestasiswithtightjunctionprotein2deficiency AT danovidavide humanipscderivedhepatocytesystemmodelscholestasiswithtightjunctionprotein2deficiency AT hayashihisamitsu humanipscderivedhepatocytesystemmodelscholestasiswithtightjunctionprotein2deficiency AT thompsonrichardj humanipscderivedhepatocytesystemmodelscholestasiswithtightjunctionprotein2deficiency AT rashidstamir humanipscderivedhepatocytesystemmodelscholestasiswithtightjunctionprotein2deficiency AT asaiakihiro humanipscderivedhepatocytesystemmodelscholestasiswithtightjunctionprotein2deficiency |